TY - JOUR
T1 - Intraoperative chemotherapy with a novel regimen improved the therapeutic outcomes of colorectal cancer
AU - Liu, Zhihua
AU - Zou, Yifeng
AU - Rong, Yuming
AU - Shi, Xingyuan
AU - Li, Chen
AU - Li, Chao
AU - Tian, Yinghai
AU - Lin, Hongcheng
AU - Liu, Min
AU - Weng, Jinsheng
AU - Liu, Ting
AU - Li, Xiaomei
AU - Lei, Chao
AU - Li, Weipeng
AU - Zhou, Xinke
N1 - Funding Information:
This work was financially supported by National Natural Science Foundation of China (No. 81670480, 81673206, 81570189), High level talents in Guangdong Province special support plan - Youth Science and technology innovation talents (2015TQ01R334), Major Scientific Research Projects at Provincial Level in Guangdong General University (2017KZDXM068), Innovation Team Project of Guangzhou Education Bureau (201831828), and Project of Guangzhou Chinese Medicine Bureau (20162095). The authors have declared that no conflict of interest exists.
Publisher Copyright:
© The author(s).
PY - 2019
Y1 - 2019
N2 - Background: This study sought to evaluate the efficacy of a novel intraoperative chemotherapy (IOC) regimen that consists of hydroxycamptothecin, tumor necrosis factor (TNF), 5-fluorouracil (5-FU), and calcium folinate (CF) on the outcomes of colorectal cancer (CRC). Methods: In total, 551 CRC patients who had undergone surgical resection were evaluated. Among these patients, 247 were treated with postoperative adjuvant chemotherapy, and 193 were treated with intraoperative chemotherapy. Of the CRC patients who underwent chemotherapy, 52 were treated with both postoperative adjuvant chemotherapy and intraoperative chemotherapy. Patients’ characteristics, including age, sex, stage, differentiation, lymph node metastasis, surgical-pathological staging, tumor location, tumor size, and relapse-free survival, were collected. Results: IOC for CRC therapy was associated with a more favorable survival prognosis (HR, 0.30, 95%CI, 0.19-0.48, P<0.001) independent of other clinical covariates. CRC patients treated with IOC survived longer than patients who were not treated with IOC did during surgery (P<0.0001, Kaplan-Meier log rank). Meanwhile, a Kaplan-Meier analysis demonstrated that individuals who received both IOC and POC survived longer than patients who received only POC: for stage II and stage III patients (P=0.0001, Kaplan-Meier log rank), stage II patients alone (P=0.02, Kaplan-Meier log rank), and stage III patients alone (P=0.046, Kaplan-Meier log rank). Conclusions: The therapeutic effects of colorectal cancer by intraoperative chemotherapy with a novel regimen were enhanced, which improved the prognosis of patients with CRC.
AB - Background: This study sought to evaluate the efficacy of a novel intraoperative chemotherapy (IOC) regimen that consists of hydroxycamptothecin, tumor necrosis factor (TNF), 5-fluorouracil (5-FU), and calcium folinate (CF) on the outcomes of colorectal cancer (CRC). Methods: In total, 551 CRC patients who had undergone surgical resection were evaluated. Among these patients, 247 were treated with postoperative adjuvant chemotherapy, and 193 were treated with intraoperative chemotherapy. Of the CRC patients who underwent chemotherapy, 52 were treated with both postoperative adjuvant chemotherapy and intraoperative chemotherapy. Patients’ characteristics, including age, sex, stage, differentiation, lymph node metastasis, surgical-pathological staging, tumor location, tumor size, and relapse-free survival, were collected. Results: IOC for CRC therapy was associated with a more favorable survival prognosis (HR, 0.30, 95%CI, 0.19-0.48, P<0.001) independent of other clinical covariates. CRC patients treated with IOC survived longer than patients who were not treated with IOC did during surgery (P<0.0001, Kaplan-Meier log rank). Meanwhile, a Kaplan-Meier analysis demonstrated that individuals who received both IOC and POC survived longer than patients who received only POC: for stage II and stage III patients (P=0.0001, Kaplan-Meier log rank), stage II patients alone (P=0.02, Kaplan-Meier log rank), and stage III patients alone (P=0.046, Kaplan-Meier log rank). Conclusions: The therapeutic effects of colorectal cancer by intraoperative chemotherapy with a novel regimen were enhanced, which improved the prognosis of patients with CRC.
KW - Colorectal cancer
KW - Intraoperative chemotherapy
KW - Prognosis
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85075886862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075886862&partnerID=8YFLogxK
U2 - 10.7150/jca.35450
DO - 10.7150/jca.35450
M3 - Article
C2 - 31762808
AN - SCOPUS:85075886862
SN - 1837-9664
VL - 10
SP - 5986
EP - 5991
JO - Journal of Cancer
JF - Journal of Cancer
IS - 24
ER -